Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease

European Journal of Haematology

Volumn 89, Issue 4, 2012, Pages 340-344

  Tovar, Natalia ^a,b   Cibeira, Ma Teresa ^a,b   Rosiñol, Laura ^a,b   Solé, Manel ^a,b   De Larrea, Carlos Fernández ^a,b   Escoda, Lourdes ^c   Rovira, Montserrat ^a,b   Bladé, Joan ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Autologous stem cell transplantation; Bortezomib; Kidney transplant; Light chain deposition disease

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW EXAMINATION; CASE REPORT; DIALYSIS; DRUG MEGADOSE; FEMALE; GLOMERULAR DEPOSITION DISEASE; GLOMERULOSCLEROSIS; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIGHT CHAIN DEPOSITION DISEASE; MULTIPLE CYCLE TREATMENT; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; BORONIC ACIDS; COMBINED MODALITY THERAPY; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 84866355112     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01821.x     Document Type: Article

References (19)

1. Sakakima M, Fujigaki Y, Tsuji T, Fukasawa H, Miyaji T, Naito K, Yamamoto T, Yonemura K, Ohnishi K, Hishida A. High dose chemotherapy and stem cell support in a patient of light and heavy-chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein. Intern Med 2005;44:970-4.
2. Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadijkonstatinou V, Dimopoulus M. Treatment of light chain deposition disease with bortezomib and dexamethasone. Hematologica 2009;94:300-302.
3. Minarik J, Scudla V, Tichy T, Pika T, Bacovsky J, Lochman P, Zadrazil J. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement. Leuk Lymphoma 2012;53:330-1.
4. Gertz MA. Managing light chain deposition disease. Leuk Lymphoma 2012;53:183-4.
5. Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006;1:1342-1350.
6. Joh K. Pathology of glomerular deposition diseases and fibrillary glomerulopathies associated with paraproteinemia and hematopoietic disorder. Nephrology (Carlton) 2007;12(Suppl 3):S21-4.
7. Ronco P, Alyanakian M, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at molecular level. J Am Soc Nephrol 2001;12:1558-1565.
8. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D'Agati VD, Leung N. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012;7:231-9.
9. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004;65:642-8.
10. Salant DJ, Sanchorawala V, D'Agati V. A case of atypical light chain deposition disease diagnosis and treatment. Clin J Am Soc Nephrol 2007;2:858-876.
11. Hassoun H, Flombaum C, D'Agati VD, et al.High dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008;42:405-412.
12. Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig M, Skinner M, Seldin DC, Sanchorawala V. Clinical and molecular characteristics of patients with non amyloid light chain deposition disorders, and outcome following treatment with high dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006;38:339-343.
13. Okura T, Miyoshi K, Nagao T, Jotoku M, Enomoto D, Irita J, Kurata M, Higaki J. Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance. Inter med 2009;48:101-104.
14. Telio D, Shepherd J, Forrest D, Zypchen L, Barnett M, Nevill T, Song KW. High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease. Bone Marrow Transplant 2012;47:453-5.
15. Lorenz E, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N. Long term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrology Dial Transplant 2008;23:2052-2057.
16. Short AK, O'Donoghue DJ, Riad HN, Short CD, Roberts IS. Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. American Journal of Nephrology 2001;21:237-40.
17. Kastritis E, Anagnostopoulos A, Roussou M, et al.Treatment of light chain (AL) amyloidosis with the combination of bortezomib dexamethasone. Hematologica 2007;92:1351-1358.
18. Gharwan H, Truica CI. Botezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure. Med Oncol 2012;29:1197-201.
19. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010;115:3655-63.